Effect of combination therapy with lactoferrin and antibiotics against staphylococcal mastitis on drying cows.
We examined combination therapy with both lactoferrin (Lf) and antibiotics on clinical mastitis due to Staphylococcus aureus (S.aureus) on drying cows. The clinical symptoms of mastitic quarters were cured 81% of combination therapeutic quarters at 7 days post injection (dpi). Moreover, most of mammary gland secretions (MGSs) in combination therapeutic quarters were normal at 7 days after parturition. In the quarters with combination therapy, S.aureus counts, Lf concentrations and content rate of concanavalin A (Con A) low-affinity Lf decreased and were lower than in the quarters treated with Lf or antibiotics alone. The mRNA expression of tumor necrosis factor alpha (TNFalpha) of the quarters with combination therapy also decreased and was lower than that of the Lf or antibiotics treated. The mRNA expression of pro-inflammatory cytokines and chemokines in bovine mammary gland epithelial lined cells (BMEC) stimulated with Lf were lower than those of Con A low-affinity Lf stimulated BMEC. Moreover, Lf showed an inhibitory effect to the induction of pro-inflammatory cytokine mRNA expression when co-stimulated with Lf and Con A low-affinity Lf. Nuclear factor kappa B (NFkappaB) activation was also induced with Con A low-affinity Lf, and the inhibitory effects of Lf were also confirmed on BMEC co-stimulated with Lf and Con A low-affinity Lf. These results indicated that the efficacy of combination therapy with antibiotics and Lf caused antibacterial effect of antibiotics and inhibition of pro-inflammatory cytokine and chemokine production with Lf via the inhibition of NFkappaB activation.
Komine
Yumiko
Y
T-Cell Research Institute, In Kyouritsu Seiyaku Co., Tokyo 102-0074, Japan.
Komine
Ken-Ichi
K
Kai
Kenzou
K
Itagaki
Masashi
M
Kuroishi
Toshinobu
T
Aso
Hisashi
H
Obara
Yoshiaki
Y
Kumagai
Katsuo
K
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002417:Cattle; D002511:Cephalosporins / Q000627:therapeutic use*; D003208:Concanavalin A / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D004359:Drug Therapy, Combination; D015180:Electrophoresis, Gel, Two-Dimensional / Q000662:veterinary; D005260:Female; D007781:Lactoferrin / Q000627:therapeutic use*; D008414:Mastitis, Bovine / Q000188:drug therapy* / Q000276:immunology; D016328:NF-kappa B / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000662:veterinary; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000276:immunology / Q000662:veterinary*; D013211:Staphylococcus aureus / Q000254:growth & development*
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D016207:Cytokines; D016328:NF-kappa B; D012333:RNA, Messenger; D003208:Concanavalin A; D007781:Lactoferrin